ArticleDiscover oncology2025
Detection of circulating tumor cells and microemboli in the blood of lung adenocarcinoma in situ patients case reports.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBased on the pathological characteristics of lung adenocarcinoma in situ (AIS), conventional histopathological understanding suggests that non-small cell lung cancer (NSCLC) cells should not penetrate the basement membrane to enter systemic circulation. When cancer cells enter the blood circulation and form circulating tumor cells (CTCs) or even circulating tumor microemboli (CTM), they may trigger cancer metastasis. CASE PRESENTATION: In three AIS patients, we detected heterogeneous populations of CTCs and CTM in peripheral blood using the CTCBIOPSY® system-a finding that possibly contradicts established AIS pathomorphological criteria.
conclusionOur findings suggest that CTCs/CTM may possess occult metastatic potential, indicating a dormant risk of micrometastasis even in AIS. Therefore, we believe that CTCs/CTM can serve as essential preoperative examination indicators for evaluating the prognosis of lung cancer patients and determining their treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.